However, the involvement of COX-2 inhibitors in gastric cancer prophylaxis remains to be determined, as the long-term use of COX-2 inhibitors exerts side-effects on the cardiovascular system and the digestive tract. The gene discussed is PTGS2; the disease is gastric cancer.